Skip to content
NMN (nicotinamide mononucleotide) / Studies
Small molecule · 334.2 Da

NMN (nicotinamide mononucleotide) studies and research data

PepBank has 217 NMN studies with results. 202 of them gave NMN, with 1,513 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.

Searches 1,513 results and 303 papers. Newer studies from Europe PMC

Results in people
124
8% of 1,513 results
Results in animals
1,080
71% of 1,513 results
Results in lab cells
301
20% of 1,513 results
From computer models
8
under 1% of 1,513 results
The molecule

NMN identity

Identifiers, parent molecule, targets and development stage, from curated data.

Beta-NMN is a ribonucleotide in NAD+ biosynthesis. Its beta-D-ribofuranosyl form is defined by PubChem and GSRS. It is a precursor, not the same compound as NAD+, nicotinamide riboside or nicotinamide. FDA changed its drug-preclusion interpretation in September 2025. Its December 2025 letter states that NMN is not excluded from the dietary supplement definition. This is not drug approval.

Kind
Small molecule
Formula
C11H15N2O8P
Identifiers
ChEMBLCHEMBL610238 (opens in a new tab)PubChem CID14180 (opens in a new tab)UNII2KG6QX4W0V (opens in a new tab)CAS1094-61-7
Parent
Precursor of NAD+NMN is a biosynthetic precursor of NAD+. This is a metabolic relation, not a peptide sequence relation.
Development
Phase 2Multiple academic and commercial programsRegistry NCT07013591 lists phase 2 and identifies MIB-626 as an oral crystalline NMN formulation. NCT06991712 also lists phase 2 with NMN. Multiple academic and commercial programs exist. This check does not establish a worldwide maximum phase across every formulation or combination. Source (opens in a new tab)

Targets

No molecular target is recorded.

Structure

Structure from the identity record.

2D structure

Draws the structure in your browser with RDKit (about 2.3 MB, loaded once).

SMILES fromPubChem CID 14180(opens in a new tab)

C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)[O-])O)O)C(=O)N
Results by area

What the studies measured

People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.

Trials and papers
Status and safety
Data

Compare